1887

Journal of General Virology header logo

Volume 83, Issue 4

Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques Free

Abstract

In the present study, the immunogenicity and protective efficacy of a recombinant vaccinia virus-based simian immunodeficiency virus (SIV) vaccine, given alone or in combination with a protein boost, were investigated. Cynomolgus macaques were immunized intramuscularly with modified vaccinia virus Ankara (MVA) expressing the SIVsm and – genes (MVA–SIVsm) at 0 and 3 months (=4), at 0, 3 and 8 months (=4) or at 0 and 3 months followed by purified native SIVsm gp148 and recombinant SIVmac p27 in immunostimulatory complexes at 8 months (=4). One month after the last immunization, the vaccinees, together with four naive control monkeys and four monkeys immunized with wild-type MVA, were challenged intrarectally with 10 MID SIVsm. At the time of challenge, antibody titres to SIV Env and lymphocyte proliferation responses to whole viral antigen were highest in vaccinees receiving MVA–SIVsm in combination with protein immunizations. Following rectal challenge, one of these vaccinees was completely protected. A prolonged survival time was observed in two of four monkeys in each of the groups immunized with MVA–SIVsm, in two monkeys given MVA–SIVsm followed by protein and in three of four monkeys given wild-type MVA, compared with naive controls. In conclusion, one monkey given the combined vaccine was protected completely against SIVsm infection. Furthermore, immunization with MVA–SIVsm, as well as wild-type MVA alone, seemed to delay disease progression after mucosal SIV infection in a proportion of the monkeys.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-4-807
2002-04-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/4/0830807a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-4-807&mimeType=html&fmt=ahah

References

  1. Andersson S., Mäkitalo B., Thorstensson R., Franchini G., Tartaglia J., Limbach K., Paoletti E., Putkonen P., Biberfeld G. 1996; Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. Journal of Infectious Diseases 174:977–985
     [Google Scholar]
  2. Antoine G., Scheiflinger F., Dorner F., Falkner F. G. 1998; The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365–396
     [Google Scholar]
  3. Baba T. W., Liska V., Khimani A. H., Ray N. B., Dailey P. J., Penninck D., Bronson R., Greene M. F., McClure H. M., Martin L. N., Ruprecht R. M. 1999; Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nature Medicine 5:194–203
     [Google Scholar]
  4. Barnett S. W., Klinger J. M., Doe B., Walker C. M., Hansen L., Duliège A.-M., Sinangil F. M. 1998; Prime–boost immunization strategies against HIV. AIDS Research and Human Retroviruses 14:S299–S309
     [Google Scholar]
  5. Barr I. G., Sjölander A., Cox J. C. 1998; ISCOMs and other saponin based adjuvants. Advanced Drug Delivery Reviews 32:247–271
     [Google Scholar]
  6. Benson J., Chougnet C., Robert-Guroff M., Montefiori D., Markham P., Shearer G., Gallo R. C., Cranage M., Paoletti E., Limbach K., Venzon D., Tartaglia J., Franchini G. 1998; Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251: dependence on route of challenge exposure. Journal of Virology 72:4170–4182
     [Google Scholar]
  7. Blanchard T. J., Alcamí A., Andrea P., Smith G. L. 1998; Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. Journal of General Virology 79:1159–1167
     [Google Scholar]
  8. Bogers W. M. J. M., Cheng-Mayer C., Montelaro R. C. 2000; Developments in preclinical AIDS vaccine efficacy models. AIDS 14:Suppl. 3S141–S151
     [Google Scholar]
  9. Chakrabarti S., Sisler J. R., Moss B. 1997; Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23:1094–1097
     [Google Scholar]
  10. de Vries P., Heeney J. L., Boes J., Dings M. E., Hulskotte E. G., Dubbes R., Koornstra W., ten Haaft P., Åkerblom L., Eriksson S. and others 1994; Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 12:1443–1452
     [Google Scholar]
  11. Excler J.-L., Plotkin S. 1997; The prime–boost concept applied to HIV preventive vaccines. AIDS 11:Suppl. AS127–S137
     [Google Scholar]
  12. Gilljam G. 1993; Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses. AIDS Research and Human Retroviruses 9:431–438
     [Google Scholar]
  13. Hanke T., Samuel R. V., Blanchard T. J., Neumann V. C., Allen T. M., Boyson J. E., Sharpe S. A., Cook N., Smith G. L., Watkins D. I., Cranage M. P., McMichael A. J. 1999; Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. Journal of Virology 73:7524–7532
     [Google Scholar]
  14. Heeney J. L., van Els C., de Vries P., ten Haaft P., Otting N., Koornstra W., Boes J., Dubbes R., Niphuis H., Dings M. and others 1994; Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. Journal of Experimental Medicine 180:769–774
     [Google Scholar]
  15. Heeney J. L., Beverley P., McMichael A., Shearer G., Strominger J., Wahren B., Weber J., Gotch F. 1999; Immune correlates of protection from HIV and AIDS – more answers but yet more questions. Immunology Today 20:247–251
     [Google Scholar]
  16. Heeney J. L., Koopman G., Rosenwirth B., Bogers W., van Dijk J., Nieuwenhuis I., Niphuis H., ten Haaft P., Hanke T., Rhodes G., Berglund P., Burny A., Bex F., Sutter G., Liljeström P. 2000; A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens. Journal of Medical Primatology 29:268–273
     [Google Scholar]
  17. Hirsch V. M., Fuerst T. R., Sutter G., Carroll M. W., Yang L. C., Goldstein S., Piatak M. Jr, Elkins W. R., Alvord W. G., Montefiori D. C., Moss B., Lifson J. D. 1996; Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. Journal of Virology 70:3741–3752
     [Google Scholar]
  18. Learmont J. C., Geczy A. F., Mills J., Ashton L. J., Raynes-Greenow C. H., Garsia R. J., Dyer W. B., McIntyre L., Oelrichs R. B., Rhodes D. I., Deacon N. J., Sullivan J. S. 1999; Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. New England Journal of Medicine 340:1715–1722
     [Google Scholar]
  19. Lövgren K., Morein B. 1988; The requirements of lipids for the formation of immunostimulating complexes (iscoms). Biotechnology and Applied Biochemistry 10:161–172
     [Google Scholar]
  20. Mäkitalo B., Böttiger P., Biberfeld G., Thorstensson R. 2000; Cell-mediated immunity to low doses of SIVsm in cynomolgus macaques did not confer protection against mucosal rechallenge. Vaccine 19:298–307
     [Google Scholar]
  21. Mulligan M. J., Weber J. 1999; Human trials of HIV-1 vaccines. AIDS 13:Suppl. AS105–S112
     [Google Scholar]
  22. Nilsson C., Thorstensson R., Gilljam G., Sjölander S., Hild K., Broliden K., Åkerblom L., Morein B., Biberfeld G., Putkonen P. 1995; Protection against monkey-cell grown cell-free HIV-2 challenge in macaques immunized with native HIV-2 envelope glycoprotein gp125. Vaccine Research 4:165–175
     [Google Scholar]
  23. Nilsson C., Mäkitalo B., Berglund P., Bex F., Liljeström P., Sutter G., Erfle V., ten Haaft P., Heeney J., Biberfeld G., Thorstensson R. 2001; Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19:3526–3536
     [Google Scholar]
  24. Ourmanov I., Brown C. R., Moss B., Carroll M., Wyatt L., Pletneva L., Goldstein S., Venzon D., Hirsch V. M. 2000; Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. Journal of Virology 74:2740–2751
     [Google Scholar]
  25. Pialoux G., Excler J.-L., Rivière Y., Gonzalez-Canali G., Feuillie V., Coulaud P., Gluckman J.-C., Matthews T. J., Meignier B., Kieny M.-P., Gonnet P., Diaz I., Méric C., Paoletti E., Tartaglia J., Salomon H., Plotkin S. 1995; A prime–boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l’Agence National de Recherche sur le SIDA. AIDS Research and Human Retroviruses 11:373–381
     [Google Scholar]
  26. Piot P. 1998; The science of AIDS: a tale of two worlds. Science 280:1844–1845
     [Google Scholar]
  27. Polacino P., Stallard V., Montefiori D. C., Brown C. R., Richardson B. A., Morton W. R., Benveniste R. E., Hu S.-L. 1999a; Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. Journal of Virology 73:3134–3146
     [Google Scholar]
  28. Polacino P. S., Stallard V., Klaniecki J. E., Pennathur S., Montefiori D. C., Langlois A. J., Richardson B. A., Morton W. R., Benveniste R. E., Hu S.-L. 1999b; Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques. Journal of Virology 73:8201–8215
     [Google Scholar]
  29. Putkonen P. 1996; Live attenuated AIDS vaccines. The Immunologist 4:142–146
     [Google Scholar]
  30. Quesada-Rolander M., Mäkitalo B., Thorstensson R., Zhang Y.-J., Castanos-Velez E., Biberfeld G., Putkonen P. 1996; Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. AIDS Research and Human Retroviruses 12:993–999
     [Google Scholar]
  31. Rhodes D. I., Ashton L., Solomon A., Carr A., Cooper D., Kaldor J., Deacon N. 2000; Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. Journal of Virology 74:10581–10588
     [Google Scholar]
  32. Seth A., Ourmanov I., Kuroda M. J., Schmitz J. E., Carroll M. W., Wyatt L. S., Moss B., Forman M. A., Hirsch V. M., Letvin N. L. 1998; Recombinant modified vaccinia virus Ankara–simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proceedings of the National Academy of Sciences, USA 95:10112–10116
     [Google Scholar]
  33. Seth A., Ourmanov I., Schmitz J. E., Kuroda M. J., Lifton M. A., Nickerson C. E., Wyatt L., Carroll M., Moss B., Venzon D., Letvin N. L., Hirsch V. M. 2000; Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag–Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. Journal of Virology 74:2502–2509
     [Google Scholar]
  34. Sutter G., Moss B. 1992; Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proceedings of the National Academy of Sciences, USA 89:10847–10851
     [Google Scholar]
  35. ten Haaft P., Verstrepen B., Überla K., Rosenwirth B., Heeney J. 1998; A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian–human immunodeficiency virus-infected macaques. Journal of Virology 72:10281–10285
     [Google Scholar]
  36. Thorstensson R., Walther L., Putkonen P., Albert J., Biberfeld G. 1991; A capture enzyme immunoassay for detection of HIV-2/SIV antigen. Journal of Acquired Immune Deficiency Syndromes 4:374–379
     [Google Scholar]
  37. Verschoor E. J., Mooij P., Oostermeijer H., van der Kolk M., ten Haaft P., Verstrepen B., Sun Y., Morein B., Åkerblom L., Fuller D. H., Barnett S. W., Heeney J. L. 1999; Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in rhesus macaques: evidence for viral clearance. Journal of Virology 73:3292–3300
     [Google Scholar]
  38. Walther L., Grankvist O., Mirzai B., Da Silva Z., Fredlund H., Biberfeld G., Thorstensson R. 1998; Optimization of polymerase chain reaction for detection of HIV type 2 DNA. AIDS Research and Human Retroviruses 14:1151–1156
     [Google Scholar]
  39. Zhang Y.-J., Fredriksson R., McKeating J. A., Fenyö E. M. 1997; Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 238:254–264
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-4-807
Loading
Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques
J. Gen. Virol. 83, 807 (2002); https://doi.org/10.1099/0022-1317-83-4-807
/content/journal/jgv/10.1099/0022-1317-83-4-807
/content/journal/jgv/10.1099/0022-1317-83-4-807
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error